Relatedly, and so long as there is no legal or commercial sensitivity, surely it is better to publish the results sooner rather than later.
The new indications represent a significant opportunity for Neuren. As things stand, NNZ-2591 is partially proved up: there are three successful Phase II trials which all started as successful mouse models.
If the new indications also demonstrate success in mouse models, there is no reason they cannot advance to Phase II and (if successful) Phase III trials. It seems to make sense to keep the market, and potential acquirers, apprised of this information rather than keeping it covered.
My preference is for all indications to be advanced as quickly as resources allow so that, when the time comes for partnering or licensing or acquisition, Neuren is in the strongest position possible.
NEU Price at posting:
$12.01 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)